Page 3,880«..1020..3,8793,8803,8813,882..3,8903,900..»

PLEGRIDY (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis

Posted: Published on July 23rd, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) announced that the European Commission (EC) has granted marketing authorization for PLEGRIDYTM (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). PLEGRIDY is dosed once every two weeks and is administered subcutaneously with the PLEGRIDY PEN, a new ready-to-use autoinjector, or a prefilled syringe. PLEGRIDY offers people living with MS an interferon with compelling efficacy that requires considerably fewer injections than other platform therapies," said George A. Scangos, Ph.D., chief executive officer at Biogen Idec. The approval of PLEGRIDY demonstrates our commitment to improving the lives of patients by providing innovative therapies that meet their individual needs, including flexibility in managing their disease. PLEGRIDY, the only pegylated interferon approved for use in RRMS, has been proven to significantly reduce important measures of disease activity, including number of relapses, MRI brain lesions, and disability progression. The EC approval of PLEGRIDY is based on results from one of the largest pivotal studies of a beta interferon conducted, ADVANCE1, which involved more than 1,500 patients with relapsing forms of MS. In the ADVANCE clinical trial, PLEGRIDY, dosed once every two weeks, significantly reduced annualized relapse … Continue reading

Posted in MS Treatment | Comments Off on PLEGRIDY (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis

Stem Cells: Promises and Reality

Posted: Published on July 23rd, 2014

Renowned Israeli stem-cell researcher in Fairfield Aug. 6 By Cindy Mindell Dr. Yaqub Hanna A leading Israeli scientist who has pioneered groundbreaking stem-cell reprogamming research will discuss his work on Wednesday, Aug. 6 at Jewish Senior Services in Fairfield. Together with a team of researchers at the Weizmann Institute of Science Department of Molecular Genetics in Rehovot, Israel, Dr. Jacob (Yaqub) Hanna has overcome a major roadblock in the use of human stem cells for medical purposes. Funded by a grant from the Israel Cancer Research Fund, their pioneering breakthrough was recently published in the peer-reviewed international science journal, Nature. Its not only Hannas work that is note-worthy: the award-winning research scientist is a Palestinian living in Israel, a native of Kafr Rama in the Galilee and the son of two medical doctors. Hanna earned a BS in medical sciences summa cum laude in 2001, an MS in microbiology and immunology in 2003, and a PhD-MD in immunology summa cum laude in 2007, all from the Hebrew University of Jerusalem, where he was among the top five percent of all Israeli medical-school graduates. After completing his PhD, Hanna decided to abandon clinical medicine and focus on research, and spent four … Continue reading

Posted in Stem Cell Research | Comments Off on Stem Cells: Promises and Reality

Genetics of cancer: Non-coding DNA can finally be decoded

Posted: Published on July 23rd, 2014

Cancer is a disease of the genome resulting from a combination of genetic modifications (or mutations). We inherit from our parents strong or weak predispositions to developing certain kinds of cancer; in addition, we also accumulate new mutations in our cells throughout our lifetime. Although the genetic origins of cancers have been studied for a long time, researchers were not able to measure the role of non-coding regions of the genome until now. A team of geneticists from the University of Geneva (UNIGE), by studying tissues from patients suffering from colorectal cancer, have succeeded in decoding this unexplored, but crucial, part of our genome. Their results can be found in Nature. To better understand how cancer develops, scientists strive to identify genetic factors -- whether hereditary or acquired -- that could serve as the catalyst or trigger for tumor progression. Until now, the genetic basis of cancers had only been examined in the coding regions of the genome, which constitutes only 2% of it. However, as recent scientific advances have shown, the other 98% is far from inactive: it includes elements that serve to regulate gene expression, and therefore should play a major role in the development of cancer. In … Continue reading

Comments Off on Genetics of cancer: Non-coding DNA can finally be decoded

Sarah Palin Claims God Wants President Obama Impeached – Video

Posted: Published on July 23rd, 2014

Sarah Palin Claims God Wants President Obama Impeached Sarah Palin claims that God wants Obama to be impeached http://www.politicususa.com/2014/07/20/sarah-palin-claims-god-president-obama-impeached.html --On the Bonus Show: A Russian man beats... By: David Pakman Show … Continue reading

Comments Off on Sarah Palin Claims God Wants President Obama Impeached – Video

NYSCF partners with Beyond Batten Disease Foundation to fight juvenile Batten disease

Posted: Published on July 23rd, 2014

PUBLIC RELEASE DATE: 23-Jul-2014 Contact: David McKeon dmckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation NEW YORK, NY -- The New York Stem Cell Foundation (NYSCF) and Beyond Batten Disease Foundation (BBDF) have partnered to develop stem cell resources to investigate and explore new treatments and ultimately find a cure for juvenile Batten disease, a fatal illness affecting children. NYSCF scientists will create induced pluripotent stem (iPS) cell lines from skin samples of young people affected by juvenile Batten disease as well as unaffected family members. IPS cell lines are produced by artificially "turning back the clock" on skin cells to a time when they were embryonic-like and capable of becoming any cell in the body. Reprogramming juvenile Batten iPS cells to become brain and heart cells will provide the infrastructure needed to investigate what is going wrong with the cells adversely affected by the disease. Thus far, efforts to study juvenile Batten disease have been done using rodent models or human skin cells, neither of which accurately mimic the disease in the brain, leaving researchers without proper tools to study the disease or a solid platform for testing drugs that prevent, halt, or reverse its progression. This will be the … Continue reading

Comments Off on NYSCF partners with Beyond Batten Disease Foundation to fight juvenile Batten disease

femtomedicine.com

Posted: Published on July 23rd, 2014

Free traffic, earnings, ip, location, rankings report for femtomedicine.com This is a free and comprehensive report about femtomedicine.com. The domain femtomedicine.com is currently hosted on a server located in Secaucus NJ, United States with the IP address 66.45.249.130. In Secaucus NJ, United States the local currency is USD ($). The website femtomedicine.com is expected to be earning an estimated $0 USD per day. If femtomedicine.com was to be sold it would possibly only be worth $10 USD (the typical cost of the registration fee for the domain name). According to our google pagerank analysis, the url femtomedicine.com currently has a pagerank of 0/10. Our records indicate that femtomedicine.com receives an estimated 0 unique visitors each day - this website is not very popular. Note: All traffic and earnings values are estimates only. Add this button to your website for free - it updates automatically! Domain names in the .com and .net domains can now be registered with many different competing registrars. Go to http://www.internic.net for detailed information. Domain Name: FEMTOMEDICINE.COM Registrar: MESH DIGITAL LIMITED Whois Server: whois.meshdigital.com Referral URL: http://www.meshdigital.com Name Server: NS1.MANAGEMENTSERVER.NET Name Server: NS2.MANAGEMENTSERVER.NET Status: clientDeleteProhibited Status: clientTransferProhibited Status: clientUpdateProhibited Updated Date: 08-may-2014 Creation Date: 12-feb-2010 Expiration Date: … Continue reading

Posted in Femtomedicine | Comments Off on femtomedicine.com

Utah positioned to become leader in cancer therapeutics industry

Posted: Published on July 23rd, 2014

Utah positioned to become leader in cancer therapeutics industry By Elenor Heyborne, KSL.com Contributor July 23rd, 2014 @ 11:45am Cancer therapeutics and drug discovery are vital areas of research and are constantly evolving as we seek to find new methods to cure the disease and develop new treatment options. With its world-class research institutions and a history of genetic discovery, Utah is positioned to become a leader in the cancer therapeutics industry. Two Utah companies, Mesagen and TheraTarget, are ahead of the curve in Utah when it comes to the advancement of cancer therapeutics. Mesagen is a Salt Lake City-based biological company working on cancer stem cell therapeutics, based in the Utah Science Technology and Research Initiative (USTAR) supported by BioInnovations Gateway. The company has acquired a proteomic database from Myriad Pharmaceuticals which contains 35,000 different protein-protein interactions representing over 5,500 different human proteins. The database is used to discover protein ligands that bind to therapeutic targets for cancer stem cell therapy. Scott Morham, CEO and CSO of Mesagen, said we get cancer every day, 24 hours a day and seven days a week. Our immune systems mostly wipe the cancer out, but every now and again an early progenitor … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Utah positioned to become leader in cancer therapeutics industry

Iodine may alleviate swelling in retinitis pigmentosa patients' retinas

Posted: Published on July 23rd, 2014

PUBLIC RELEASE DATE: 21-Jul-2014 Contact: Mary Leach Mary_Leach@meei.harvard.edu Massachusetts Eye and Ear Infirmary Boston Cystoid macular edema (CME) is a common complication of retinitis pigmentosa (RP), a family of retinal diseases in which patients typically lose night and side vision first and then develop impaired central vision. CME can also decrease central vision. Current treatments for CME in RP are not always effective and can lead to adverse results. Researchers from the Massachusetts Eye and Ear, Harvard Medical School, and Boston University School of Medicine tested whether the extent of retinal swelling due to CME was inversely related to dietary iodine intake in patients with RP and found that it was. This finding raises the possibility that an iodine supplement could help limit or reduce central foveal swelling in RP patients with CME. Their results are presented online in the July issue of JAMA Ophthalmology. Past research performed on a previous population showed an inverse association between the presence of CME and reported iodine supplementation in RP patients. This finding and physiology research by others pointed to iodine as being worth investigating further. In the present experiment, the researchers performed a cross-sectional observational study of 212 nonsmoking patients 18 to … Continue reading

Posted in Retinitis Pigmentosa | Comments Off on Iodine may alleviate swelling in retinitis pigmentosa patients' retinas

Stem cell drive to be held Sunday

Posted: Published on July 23rd, 2014

Published Jul 23, 2014 at 1:29 pm (Updated Jul 23, 2014) SPARTA On Sunday, July 27 there will be a stem cell drive from 8 a.m. to 2 p.m. in Cassidy Hall at Our Lady of the Lake Church in Sparta. Erik Massenzio has organized the drive through "Be The Match" which is a national registry for patients who are searching for a donor in order to receive a stem cell transplant. His mother, Hedy Massenzio, who was in need of a donor due to a diagnosis of acute leukemia, received a life saving transplant ten years ago from a donor who was in the national registry. There are many misconceptions about stem cell, also known as bone marrow transplants, and part of the purpose of the drive is to educate potential donors of the procedure of donation. While many people still believe that surgery is involved, today the method of donation is primarily a simple blood donation at a local blood bank. '); //--> Signing up to be in the registry is very simple and quick. You must be between the ages of 18 to 44, and it only involves a self-administered inner cheek swab. Most people who are … Continue reading

Posted in Stem Cell Transplant | Comments Off on Stem cell drive to be held Sunday

Justice minister won't interfere with Stamina court decision

Posted: Published on July 23rd, 2014

'Ministry can't interfere with judges' Orlando tells Senate (ANSA) - Rome, July 23 - Justice Minister Andrea Orlando told the Senate health committee Wednesday that the ministry can't interfere with a court ruling that forced a hospital to administer the controversial Stamina stem-cell treatment to an ailing boy. His statement came after a court ordered the treatment administered to a child suffering from muscular dystrophy at a hospital in northern Italy on Tuesday, despite the fact that it has been discredited by many in the scientific community. The Stamina treatment was administered on the orders of a Sicilian court after the hospital in Brescia decided to suspend the procedure because it had been called into doubt. The justice ministry "cannot interfere with the court's decisions. The judge has freedom of interpretation," Orlando told MPs. "However, no amount of court rulings can fill what is a legislative void on this issue," he added. The credibility of the Stamina treatment - which involves extracting bone-marrow stem cells from a patient, supposedly turning them into neurons by exposing them to retinoic acid for two hours, and injecting them back into the patient - has long been suspect, and last autumn the health ministry … Continue reading

Comments Off on Justice minister won't interfere with Stamina court decision

Page 3,880«..1020..3,8793,8803,8813,882..3,8903,900..»